¼¼°èÀÇ ¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅÍ ½ÃÀå
Vaccine Vial Monitors
»óǰÄÚµå : 1795194
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 273 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅÍ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 3¾ï 4,010¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 2¾ï 3,300¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅÍ ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 3¾ï 4,010¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¸ÖƼ µµ½º ¸ð´ÏÅÍ´Â CAGR 5.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 8,810¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÏȸ Åõ¿© ¸ð´ÏÅÍ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 8.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 6,350¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 10.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅÍ ½ÃÀåÀº 2024³â¿¡ 6,350¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ 2024³âºÎÅÍ 2030³â±îÁö CAGR 10.0%·Î ÃßÁ¤µÇ¸ç, 2030³â¿¡´Â 6,920¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.3%¿Í 6.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅÍ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅͰ¡ Àü ¼¼°è ¹é½ÅÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» º¸ÀåÇÏ´Â µ¥ Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀϱî?

¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅÍ(VVM)´Â Á¦Á¶ºÎÅÍ Åõ¿©±îÁö ¹é½ÅÀÇ È¿´ÉÀ» À¯ÁöÇÔÀ¸·Î½á Àü ¼¼°è ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. »öÀÌ º¯ÇÏ´Â ÀÌ ÀÛÀº ÀεðÄÉÀÌÅÍ´Â ¹é½Å ¹ÙÀ̾˿¡ ºÎÂøµÇ¾î ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ´©ÀûµÇ´Â ¿­ ³ëÃâÀ» ½Ã°¢ÀûÀ¸·Î º¸¿©ÁÜÀ¸·Î½á ÀÇ·áÁøÀÌ ¹é½ÅÀÌ À§Çè¿¡ ³ëÃâµÇ¾ú´ÂÁö ¿©ºÎ¸¦ ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. Àü ¼¼°è ¸¹Àº Áö¿ª, ƯÈ÷ ¿Üµý Áö¿ªÀ̳ª ÀÚ¿øÀÌ ÇÑÁ¤µÈ Áö¿ª¿¡¼­´Â ²÷±è ¾ø´Â ÄݵåüÀÎÀ» À¯ÁöÇÏ´Â °ÍÀÌ Å« °úÁ¦ÀÔ´Ï´Ù. ¿Âµµ º¯µ¿Àº ¹é½ÅÀÇ È¿´ÉÀ» ¶³¾î¶ß¸®°Å³ª ¿ÏÀüÈ÷ ºñȰ¼ºÈ­½Ãų ¼ö ÀÖÁö¸¸, ¹é½ÅÀÇ ¿­È­ ¡Èİ¡ ¹Ýµå½Ã ´«¿¡ º¸ÀÌ´Â °ÍÀº ¾Æ´Õ´Ï´Ù. VVMÀº °íµµÀÇ ±â¼úÀ» ÇÊ¿ä·Î ÇÏÁö ¾ÊÀ¸¸ç, ÇöÀå ÀÇ·áÁøÀÌ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï µµ¿ÍÁÖ´Â °£´ÜÇÏ°í ºñ¿ë È¿À²ÀûÀÎ µµ±¸·Î ÀÛ¿ëÇÕ´Ï´Ù. È¿°ú°¡ ¾ø´Â ¹é½ÅÀÇ Åõ¿©¸¦ ¹æÁöÇÔÀ¸·Î½á °øÁß º¸°ÇÀ» º¸È£ÇÏ°í ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥¿¡ ´ëÇÑ ½Å·Ú¸¦ °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. WHO¿Í UNICEF¿Í °°Àº ±¹Á¦º¸°Ç±â±¸´Â ƯÈ÷ È«¿ª, ¼Ò¾Æ¸¶ºñ, °áÇÙ°ú °°Àº Áúº´À» ´ë»óÀ¸·Î ÇÏ´Â ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥¿¡¼­ VVMÀ» Ç¥ÁØ ¿ä±¸»çÇ×À¸·Î »ï°í ÀÖ½À´Ï´Ù. ƯÈ÷ Àü¿°º´À̳ª Àü¿°º´ ¹ß»ý¿¡ ´ëÀÀÇÏ¿© ¹é½Å Á¢Á¾ ±Ô¸ð¸¦ È®´ëÇÏ´Â ±¹°¡°¡ ´Ã¾î³²¿¡ µû¶ó ¹é½Å ¹«°á¼º À¯ÁöÀÇ Á߿伺ÀÌ ´õ¿í ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. VVMÀº ¹é½Å À¯ÅëÀÇ ¸ðµç ´Ü°è¿¡¼­ Åõ¸í¼º, Ã¥ÀÓ¼º, ¾ÈÀü¼ºÀ» Á¦°øÇϰí, º¸°ü »ç½½¿¡¼­ ÇʼöÀûÀΠüũÆ÷ÀÎÆ® ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅÍÀÇ ±â´ÉÀº ¾î¶»°Ô Çâ»óµÇ°í Àִ°¡?

¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅÍÀÇ ±â´É¼º°ú ½Å·Ú¼ºÀº Àç·á°úÇÐ, ¿­È­ÇÐ, ÁöÇ¥ ¼³°èÀÇ ¹ßÀüÀ¸·Î Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. ±âÁ¸ VVMÀº ´©ÀûµÈ ¿­ ³ëÃâ¿¡ ¹ÝÀÀÇÏ¿© »öÀÌ º¯ÇÏ´Â ½Ã°£ ¿Âµµ ¹Î°¨¼º ¿°·á¿¡ ÀÇÁ¸ÇÏ´Â ¹Ý¸é, Â÷¼¼´ë ¸ð´ÏÅÍ´Â º¸´Ù Á¤È®Çϰí ÇØ¼®Çϱ⠽¬¿ì¸ç ±¤¹üÀ§ÇÑ ¿Âµµ ÇÁ·ÎÆÄÀÏÀ» Áö¿øÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ °³¼±À» ÅëÇØ mRNA ±â¹Ý Á¦Á¦¿Í °°ÀÌ ÃÊÀú¿Â º¸Á¸ÀÌ ÇÊ¿äÇÑ ¹é½ÅÀ» Æ÷ÇÔÇÏ¿© ´Ù¾çÇÑ À¯ÇüÀÇ ¹é½Å¿¡ ÀûÇÕÇÑ VVMÀ» °³¹ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Á¢ÂøÁ¦¿Í À×Å©ÀÇ ¹èÇÕÀÌ °³¼±µÇ¾î ¿­¾ÇÇÑ Á¶°Ç¿¡¼­µµ ÀεðÄÉÀÌÅͰ¡ ´Ü´ÜÈ÷ °íÁ¤µÇ¾î °¡½Ã¼ºÀ» À¯ÁöÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Á¦Á¶¾÷üµéÀº ¶ÇÇÑ ÀÇ·áÁøÀÌ ¹ÙÀ̾ËÀÇ ¿Âµµ ÀÌ·Â, À¯È¿±â°£ ¸¸·á »óÅÂ, ¹èÄ¡ÀÇ Ãâó¿¡ ´ëÇÑ µ¥ÀÌÅ͸¦ ½ºÄµÇÏ¿© ±â·ÏÇÒ ¼ö ÀÖ´Â QRÄÚµå¿Í °°Àº µðÁöÅÐ ±â´ÉÀ» VVM¿¡ ÅëÇÕÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀϺΠÂ÷¼¼´ë VVMÀº ±Ù°Å¸® ¹«¼± Åë½Å(NFC) Ĩ°ú ºí·çÅõ½º ±â´ÉÀ» žÀçÇÏ¿© °³¹ßµÇ°í ÀÖÀ¸¸ç, ½º¸¶Æ®ÆùÀ̳ª ¿¬°áµÈ ÀåÄ¡¸¦ ÅëÇØ ½Ç½Ã°£ ¸ð´ÏÅ͸µÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº µ¥ÀÌÅÍ ¼öÁýÀ» °³¼±Çϰí, ³¶ºñ¸¦ ÁÙÀ̸ç, ¹°·ù È¥¶õ¿¡ ½Å¼ÓÇÏ°Ô ´ëÀÀÇϰíÀÚ ÇÏ´Â ¹é½Å ÆÇ¸Å¾÷ü¿Í º¸°ÇºÎ¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ¶ÇÇÑ, VVMÀÇ µðÀÚÀÎÀº º¸´Ù ¸íÈ®ÇÑ ½Ã°¢Àû Ç¥½Ã±â, º¯Á¶ ¹æÁö ±â´É, ´Ù¾çÇÑ ÇコÄɾî ȯ°æÀ» Áö¿øÇÏ´Â ´Ù±¹¾î ¼³¸í¼­ µî º¸´Ù »ç¿ëÀÚ Áß½ÉÀûÀ¸·Î º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº ÄݵåüÀο¡¼­ Áö´ÉÇü µµ±¸·Î¼­ VVMÀÇ ¿ªÇÒÀ» °­È­Çϰí, ¹é½ÅÀÇ Ç°Áú º¸ÁõÀ» °­È­Çϸç, ÀÎÀ§ÀûÀÎ ½Ç¼ö³ª º¸°ü ½ÇÆÐ¿¡ µû¸¥ À§ÇèÀ» ÁÙ¿©ÁÝ´Ï´Ù.

¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅÍÀÇ ¼ö¿ä¸¦ ÁÖµµÇÏ´Â ¼¼°è º¸°Ç ÀÌ´Ï¼ÅÆ¼ºê¿Í ½ÃÀåÀº?

Àü ¼¼°èÀûÀ¸·Î ¿¹¹æÁ¢Á¾ Ȱµ¿ÀÇ ±Ô¸ð°¡ È®´ëµÇ°í º¹ÀâÇØÁö¸é¼­ ¹é½Å, ¹ÙÀ̾Ë, ¸ð´ÏÅÍ¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ÀÎÇÁ¶ó Á¦¾àÀ¸·Î ÀÎÇØ ÄݵåüÀÎ Àå¾ÖÀÇ À§ÇèÀÌ ³ôÀº Áö¿ª¿¡¼­´Â ÀÌ·¯ÇÑ °æÇâÀÌ µÎµå·¯Áý´Ï´Ù. ƯÈ÷ Gavi, WHO, UNICEF µîÀÇ Á¶Á÷ÀÌ ÁÖµµÇÏ´Â ´ë±Ô¸ð ¿¹¹æÁ¢Á¾ ÀÌ´Ï¼ÅÆ¼ºê´Â ¾ÆÇÁ¸®Ä«, ³²¾Æ½Ã¾Æ, ¶óƾ¾Æ¸Þ¸®Ä« ÀϺΠÁö¿ª¿¡¼­ ¹èÆ÷µÇ´Â ¹é½ÅÀÇ Á¶´Þ ±âÁØ¿¡ VVMÀ» ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áö¿ª¿¡¼­´Â Àü·Â °ø±ÞÀÇ º¯µ¿¼º, ³ÃÀå ´É·ÂÀÇ Á¦ÇÑ, ±ä ¿î¼Û °æ·Î µî¿¡ Á÷¸éÇÏ´Â °æ¿ì°¡ ¸¹À¸¸ç, VVMÀº ¿­¾ÇÇÑ Á¶°Ç¿¡¼­ ¹é½ÅÀÇ È¿´ÉÀ» º¸È£ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ·ÎŸ¹ÙÀÌ·¯½º, HPV, Ȳ¿­º´ µî ±¹°¡ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥À» ½ÃÇàÇÏ´Â ±¹°¡¿¡¼­ VVV´Â Àϼ± ÀÇ·áÁøÀÌ ¹é½ÅÀ» ¾ÈÀüÇÏ°Ô Æò°¡Çϰí Åõ¿©ÇÒ ¼ö ÀÖµµ·Ï ½Å·Ú¼ºÀ» Á¦°øÇÕ´Ï´Ù. COVID-19 ¹é½ÅÀÇ Ãâ½Ã·Î ÀÎÇØ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¸ð´ÏÅ͸µÀÇ Çʿ伺ÀÌ ´õ¿í °­Á¶µÇ¾ú°í, ¸¹Àº mRNA ¹é½ÅÀº Ãʱ⿡ ÃÊÀú¿Â º¸°üÀÌ ÇÊ¿äÇßÁö¸¸, ¹°·ùÀÇ ÀûÀÀ°ú »õ·Î¿î Á¦ÇüÀ¸·Î ÀÎÇØ ÇöÀç ´õ ±¤¹üÀ§ÇÑ °øÁß º¸°Ç¿¡ »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾î Àü¹® VVM¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Áß»êÃþ ±¹°¡µéµµ ÄݵåüÀÎ Çö´ëÈ­ ³ë·ÂÀÇ ÀÏȯÀ¸·Î ÀÌ·¯ÇÑ ÁöÇ¥¸¦ äÅÃÇϰí ÀÖÀ¸¸ç, ¸¹Àº °æ¿ì ¾ç±¹ °£ º¸°Ç ÆÄÆ®³Ê½ÊÀ̳ª ÇØ¿Ü ¿øÁ¶¸¦ ÅëÇØ Áö¿ø¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à»ç ¹× Á¦Á¶ À§Å¹ ±â°üÀº ±¹Á¦ Ç¥ÁØÀ» ÃæÁ·Çϰí Á¦Ç°ÀÇ ÃßÀû¼ºÀ» º¸ÀåÇϱâ À§ÇØ VVMÀ» Á¦Á¶ ¹× À¯Åë ÇÁ·ÎÅäÄÝ¿¡ ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎ ÇÁ·Î±×·¥»Ó¸¸ ¾Æ´Ï¶ó ÀεµÀû Áö¿ø ´Üü¿Í Àç³­ ´ëÀÀ ±â°üµµ ±ä±Þ »óȲ¿¡¼­ ¾ÈÀüÇÑ ¿¹¹æÁ¢Á¾À» Á¦°øÇϱâ À§ÇØ VVMÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±¤¹üÀ§ÇÏ°í ´Ù¾çÇÑ »ç¿ë »ç·Ê·Î ÀÎÇØ ¼¼°è VVM ½ÃÀåÀº Áö¼ÓÀûÀÎ ¼ö¿ä¿Í ±â¼ú Çõ½ÅÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

¹é½Å ¹ÙÀÌ¾Ë ¹× ¸ð´ÏÅÍ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

¹é½Å ¹ÙÀÌ¾Ë ¹× ¸ð´ÏÅÍ ½ÃÀåÀÇ ¼ºÀåÀº ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ È®´ë, ¼¼°è º¸°Ç¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ±ÔÁ¦ ¿ä°Ç °­È­, ÄݵåüÀÎ Ãë¾à¼º¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µî ¸î °¡Áö ÁÖ¿ä ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. º¸ÆíÀû ¹é½Å Á¢Á¾À» ´Þ¼ºÇÏ°í ¹é½ÅÀ¸·Î ¿¹¹æ °¡´ÉÇÑ Áúº´À» ÅðÄ¡Çϱâ À§ÇØ ³ë·ÂÇÏ´Â ±¹°¡°¡ ´Ã¾î³²¿¡ µû¶ó VVM°ú °°Àº ½Å·ÚÇÒ ¼ö Àִ ǰÁú º¸Áõ µµ±¸ÀÇ Çʿ伺ÀÌ °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. GaviÀÇ COVAX ÇÁ·Î±×·¥, ¼¼°èÀºÇàÀÇ ÆÒµ¥¹Í ´ëÃ¥°ú °°Àº ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÅëÇÑ ¼¼°è ÀÚ±Ý Áö¿øµµ ÁßÀú¼Òµæ ±¹°¡¿¡¼­ VVMÀ» ±¤¹üÀ§ÇÏ°Ô Á¶´ÞÇÏ°í ½ÇÇàÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. WHO¿Í °¢±¹ º¸°ÇºÎ¸¦ Æ÷ÇÔÇÑ ±ÔÁ¦ ±â°üÀº ƯÈ÷ °ø°ø ºÎ¹®À» ÅëÇØ À¯ÅëµÇ´Â ¸ðµç ¿­°¨¼ö¼º ¹é½Å¿¡ VVM »ç¿ëÀ» Àǹ«È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¤Ã¥À¸·Î ÀÎÇØ °¢ Á¦Á¶»çµéÀº ¹é½Å ¶óÀÎ Àüü¿¡ VVM ÅëÇÕÀ» Ç¥ÁØÈ­Çϵµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àú¿Â ¶Ç´Â ÃÊÀú¿Â º¸°üÀÌ ÇÊ¿äÇÑ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϸ鼭 Á¾ÇÕÀûÀÎ ÄݵåüÀÎ °ËÁõÀÇ ÀÏȯÀ¸·Î ¿Âµµ ¹Î°¨µµ ÁöÇ¥ÀÇ Á߿伺ÀÌ ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, VVMÀÇ µðÀÚÀΰú »ç¿ë ÆíÀǼºÀÇ ±â¼úÀû Çâ»óµµ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î ¸ðµ¨Àº ¼º´É°ú µ¥ÀÌÅÍ ÃßÀû ±â´ÉÀÌ °­È­µÇ¾î ±¹Á¦º¸°Ç±â±¸¿Í »ó¾÷Àû ±¸¸ÅÀÚ ¸ðµÎ¿¡°Ô ¾îÇÊÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹é½Å Æó±â¹° °¨¼Ò¿Í °ø±Þ¸Á ÃÖÀûÈ­¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó VVMÀº Áö¼Ó°¡´É¼º ¸ñÇ¥¿¡ ±â¿©ÇÏ´Â ºñ¿ë Àý°¨ µµ±¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅÍÀÇ Àü·«Àû °¡Ä¡¸¦ °­È­ÇÏ¿© ¹é½Å ¾ÈÀü, ¹°·ù ¹× °øÁß º¸°Ç º¸Áõ¿¡ ÇʼöÀûÀÎ ÀÚ»êÀ¸·Î Áö¼ÓÀûÀÎ ¼ºÀåÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(¸ÖƼ µµ½º ¸ð´ÏÅÍ, ½Ì±Û µµ½º ¸ð´ÏÅÍ), ¿ëµµ(¿¹¹æ ¹é½Å ¿ëµµ, Ä¡·á ¹é½Å ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Vaccine Vial Monitors Market to Reach US$340.1 Million by 2030

The global market for Vaccine Vial Monitors estimated at US$233.0 Million in the year 2024, is expected to reach US$340.1 Million by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Multi-Dose Monitors, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$188.1 Million by the end of the analysis period. Growth in the Single Dose Monitors segment is estimated at 8.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$63.5 Million While China is Forecast to Grow at 10.0% CAGR

The Vaccine Vial Monitors market in the U.S. is estimated at US$63.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$69.2 Million by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Vaccine Vial Monitors Market - Key Trends & Drivers Summarized

Why Are Vaccine Vial Monitors Critical in Ensuring Vaccine Safety and Efficacy Worldwide?

Vaccine Vial Monitors (VVMs) play an indispensable role in global immunization programs by ensuring that vaccines remain effective from production to administration. These small, color-changing indicators are affixed to vaccine vials and provide a visual cue about cumulative heat exposure over time, helping health workers determine whether a vaccine has been compromised. In many parts of the world, particularly in remote or resource-limited areas, maintaining an unbroken cold chain is a significant challenge. Temperature excursions can degrade vaccines, rendering them less effective or even completely inactive, and yet the signs of degradation are not always visible. VVMs act as simple, cost-effective tools that empower frontline health workers to make informed decisions without requiring sophisticated technology. They help prevent the administration of ineffective vaccines, thus safeguarding public health and reinforcing trust in immunization programs. International health organizations such as WHO and UNICEF have made VVMs a standard requirement for vaccines supplied through their programs, especially those targeting diseases like measles, polio, and tuberculosis. As more countries scale up vaccination efforts, particularly in response to pandemics or outbreaks, the importance of maintaining vaccine integrity has become even more pronounced. VVMs serve as an essential checkpoint in the chain of custody, offering transparency, accountability, and safety across all stages of vaccine distribution.

How Are Technological Improvements Enhancing the Capabilities of Vaccine Vial Monitors?

The functionality and reliability of Vaccine Vial Monitors have been significantly improved through advances in materials science, thermal chemistry, and indicator design. Traditional VVMs rely on a time-temperature sensitive dye that changes color in response to cumulative heat exposure, but newer generations of monitors are more precise, easier to interpret, and designed for a broader range of temperature profiles. These improvements have enabled the development of VVMs suited for various types of vaccines, including those requiring ultracold storage such as mRNA-based formulations. Enhanced adhesives and ink formulations now ensure that indicators remain firmly attached and legible even under harsh conditions. Manufacturers are also working on integrating digital features with VVMs, such as QR codes that allow health workers to scan and log data related to a vial’s temperature history, expiration status, and batch origin. Some next-generation VVMs are being developed with near-field communication (NFC) chips or Bluetooth capabilities, enabling real-time monitoring via smartphones or connected devices. These technologies are particularly valuable for vaccine distributors and health ministries aiming to improve data collection, reduce waste, and respond quickly to logistical disruptions. Furthermore, VVM design is becoming more user-centric, with clearer visual indicators, tamper-evidence features, and multilingual instructions to support diverse healthcare settings. These technological advancements are reinforcing the role of VVMs as intelligent tools in the cold chain, enhancing vaccine quality assurance and reducing the risks associated with human error or storage failure.

Which Global Health Initiatives and Markets Are Driving Demand for Vaccine Vial Monitors?

The increasing scale and complexity of global vaccination efforts are driving significant demand for Vaccine Vial Monitors, especially in regions where infrastructure limitations elevate the risk of cold chain failure. Large-scale immunization initiatives, particularly those spearheaded by organizations such as Gavi, WHO, and UNICEF, have integrated VVMs into the procurement criteria for vaccines distributed in Africa, South Asia, and parts of Latin America. These regions often face fluctuating power supplies, limited refrigeration capacity, and long transportation routes, making VVMs essential for protecting vaccine efficacy under challenging conditions. In countries implementing national immunization programs for diseases like rotavirus, HPV, and yellow fever, VVMs provide frontline health workers with the confidence to assess and administer vaccines safely. The rollout of COVID-19 vaccines further emphasized the need for reliable monitoring, and while many mRNA vaccines required ultracold storage initially, logistical adaptations and new formulations are now bringing them into broader public health use, reinforcing demand for specialized VVMs. Middle-income nations are also adopting these indicators as part of broader cold chain modernization efforts, often supported by bilateral health partnerships and foreign aid. Additionally, pharmaceutical companies and contract manufacturing organizations are embedding VVMs in their production and distribution protocols to meet international standards and ensure product traceability. Beyond government programs, humanitarian aid groups and disaster response agencies also rely on VVMs to deliver safe immunizations in emergency settings. These widespread and varied use cases are ensuring sustained demand and innovation in the global VVM market.

What Key Factors Are Driving Growth in the Vaccine Vial Monitors Market?

The growth in the vaccine vial monitors market is driven by several critical factors, including expanding immunization programs, rising global health investment, increased regulatory requirements, and heightened awareness about cold chain vulnerabilities. As more countries commit to achieving universal vaccine coverage and eradicating vaccine-preventable diseases, the need for reliable quality assurance tools like VVMs continues to increase. Global funding from initiatives such as Gavi’s COVAX program and the World Bank’s pandemic preparedness efforts is also enabling broader procurement and implementation of VVMs in low- and middle-income countries. Regulatory bodies, including WHO and national ministries of health, are mandating the use of VVMs on all heat-sensitive vaccines, especially those distributed through public-sector channels. These policies are encouraging manufacturers to standardize VVM integration across their vaccine lines. Additionally, the surge in demand for vaccines requiring cold or ultracold storage is spotlighting the importance of temperature-sensitive indicators as part of comprehensive cold chain validation. Technological improvements in VVM design and usability are also fueling growth, as newer models offer enhanced performance and data tracking capabilities that appeal to both global health organizations and commercial buyers. Moreover, the increasing focus on vaccine waste reduction and supply chain optimization is positioning VVMs as cost-saving tools that also contribute to sustainability goals. Together, these factors are reinforcing the strategic value of vaccine vial monitors and ensuring their continued growth as indispensable assets in vaccine safety, logistics, and public health assurance.

SCOPE OF STUDY:

The report analyzes the Vaccine Vial Monitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Multi-Dose Monitors, Single Dose Monitors); Application (Preventive Vaccine Application, Therapeutic Vaccine Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â